3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Sarcoma
17
Rhabdomyosarcoma
14
Wilms Tumor
9
Malignant mesenchymal tumor
7
Gestational Trophoblastic Disease
6
Kidney Neoplasms
5
Neuroectodermal Tumors, Primitive, Peripheral
4
Rhabdomyosarcoma, Embryonal
3
Melanoma
3
Fibrosarcoma
3
Sarcoma, Ewing
2
Rhabdomyosarcoma, Alveolar
2
Ovarian Neoplasms
2
Liposarcoma
2
Hydatidiform Mole
2
Hemangiosarcoma
2
Hemangiopericytoma, Malignant
2
Desmoplastic Small Round Cell Tumor
2
Choriocarcinoma
2
Testicular Neoplasms
1
Teratoma, Ovarian
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Sarcoma, Alveolar Soft Part
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleuropulmonary blastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Germ Cell and Embryonal
×
Dactinomycin
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled